{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:10:06Z","timestamp":1772601006126,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Government of Uganda through Makerere University Research and Innovations Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook a prospective interventional open-label cohort study to evaluate the efficacy and tolerability of fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge and complete symptom resolution. We included 316 patients, of whom 94 received fluvoxamine in addition to standard care [median age, 60 years (IQR\u2009=\u200937.0); women, 52.2%]. Fluvoxamine use was significantly associated with reduced mortality [AHR\u2009=\u20090.32; 95% CI\u2009=\u20090.19\u20130.53; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, NNT\u2009=\u20094.46] and with increased complete symptom resolution [AOR\u2009=\u20092.56; 95% CI\u2009=\u20091.53\u20135.51; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, NNT\u2009=\u20094.44]. Sensitivity analyses yielded similar results. These effects did not significantly differ by clinical characteristic, including vaccination status. Among the 161 survivors, fluvoxamine was not significantly associated with time to hospital discharge [AHR 0.81, 95% CI (0.54\u20131.23), <jats:italic>p<\/jats:italic>\u2009=\u20090.32]. There was a trend toward greater side effects with fluvoxamine (7.45% versus 3.15%; SMD\u2009=\u20090.21; <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20093.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.06), most of which were light or mild in severity and none of which were serious. One hundred mg of fluvoxamine prescribed twice daily for 10 days was well tolerated and significantly associated with reduced mortality and with increased complete symptom resolution, without a significant increase in time to hospital discharge, among inpatients with COVID-19. Large-scale randomized trials are urgently needed to confirm these findings, especially for low- and middle-income countries, where access to vaccines and approved treatments against COVID-19 is limited.<\/jats:p>","DOI":"10.1038\/s41380-023-02004-3","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:02:28Z","timestamp":1677834148000},"page":"5411-5418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study"],"prefix":"10.1038","volume":"28","author":[{"given":"Bruce J.","family":"Kirenga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-2472","authenticated-orcid":false,"given":"Levicatus","family":"Mugenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-8641","authenticated-orcid":false,"given":"Marina","family":"S\u00e1nchez-Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-8727","authenticated-orcid":false,"given":"Henry","family":"Kyobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winters","family":"Muttamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Mugume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliya","family":"Mwesigwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra","family":"Kalimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Nyombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-1694","authenticated-orcid":false,"given":"Ivan","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loryndah Olive","family":"Namakula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogers","family":"Sekibira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilberforce","family":"Kabweru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Byanyima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-4318","authenticated-orcid":false,"given":"Hellen","family":"Aanyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-1968","authenticated-orcid":false,"given":"Pauline","family":"Byakika-Kibwika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry G.","family":"Mwebesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Hoertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bazeyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"2004_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/10408363.2020.1783198","volume":"57","author":"M Ciotti","year":"2020","unstructured":"Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57:365\u201388.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2004_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.encep.2020.04.005","volume":"46","author":"A Chevance","year":"2020","unstructured":"Chevance A, Gourion D, Hoertel N, Llorca PM, Thomas P, Bocher P, et al. Ensuring mental health care during the SARS-CoV-2 epidemic in France: a narrative review. L\u2019Enc\u00e9phale. 2020;46:193\u2013201.","journal-title":"L\u2019Enc\u00e9phale"},{"key":"2004_CR3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41591-020-1001-6","volume":"26","author":"N Hoertel","year":"2020","unstructured":"Hoertel N, Blachier M, Blanco C, Olfson M, Masseti M, S\u00e1nchez-Rico M, et al. A stochastic agent-based model of the SARS-CoV-2 epidemic in France. Nat Med. 2020;26:1417\u201321.","journal-title":"Nat Med"},{"key":"2004_CR4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","volume":"399","author":"H Wang","year":"2022","unstructured":"Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321. Lancet. 2022;399:1513\u201336.","journal-title":"Lancet"},{"key":"2004_CR5","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.2147\/RMHP.S339408","volume":"14","author":"P Musoke","year":"2021","unstructured":"Musoke P, Okot J, Nanfuka V, Rwamafa P, Masajjage J, Kisuule I, et al. A preliminary report on herbal medicine use among patients hospitalized at two-large COVID-19 treatment centers in Uganda. RMHP. 2021;14:4609\u201317.","journal-title":"RMHP"},{"key":"2004_CR6","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMc2101927","volume":"384","author":"J Keehner","year":"2021","unstructured":"Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley R, Currier JS, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774\u20135.","journal-title":"N Engl J Med"},{"key":"2004_CR7","doi-asserted-by":"crossref","first-page":"ofac389","DOI":"10.1093\/ofid\/ofac389","volume":"9","author":"S Lim","year":"2022","unstructured":"Lim S, Tignanelli CJ, Hoertel N, Boulware DR, Usher MG. Prevalence of medical contraindications to nirmatrelvir\/ritonavir in a cohort of hospitalized and nonhospitalized patients with COVID-19. Open Forum Infect Dis. 2022;9:ofac389.","journal-title":"Open Forum Infect Dis"},{"key":"2004_CR8","doi-asserted-by":"crossref","first-page":"e2242140","DOI":"10.1001\/jamanetworkopen.2022.42140","volume":"5","author":"N Hoertel","year":"2022","unstructured":"Hoertel N, Boulware DR, S\u00e1nchez-Rico M, Burgun A, Limosin F. Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease. JAMA Netw Open. 2022;5:e2242140.","journal-title":"JAMA Netw Open"},{"key":"2004_CR9","doi-asserted-by":"crossref","first-page":"e2136510","DOI":"10.1001\/jamanetworkopen.2021.36510","volume":"4","author":"N Hoertel","year":"2021","unstructured":"Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19. JAMA Netw Open. 2021;4:e2136510.","journal-title":"JAMA Netw Open"},{"key":"2004_CR10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/s41380-021-01393-7","volume":"27","author":"N Hoertel","year":"2022","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Herrera-Morueco JJ, de la Muela P, Gulbins E, Kornhuber J, et al. Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2022;27:1278\u201380.","journal-title":"Mol Psychiatry"},{"key":"2004_CR11","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1038\/s41380-021-01254-3","volume":"26","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid\/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. 2021;26:7098\u20139.","journal-title":"Mol Psychiatry"},{"key":"2004_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00023210-199401010-00006","volume":"1","author":"KJ Palmer","year":"1994","unstructured":"Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs. 1994;1:57\u201387.","journal-title":"CNS Drugs"},{"key":"2004_CR13","doi-asserted-by":"crossref","first-page":"e226269","DOI":"10.1001\/jamanetworkopen.2022.6269","volume":"5","author":"TC Lee","year":"2022","unstructured":"Lee TC, Vigod S, Bortolussi-Courval \u00c9, Hanula R, Boulware DR, Lenze EJ, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e226269.","journal-title":"JAMA Netw Open"},{"key":"2004_CR14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516\u201323.","journal-title":"Ann Med"},{"key":"2004_CR15","first-page":"00672","volume":"S0163-4453","author":"R Marcec","year":"2022","unstructured":"Marcec R, Dodig VM, Likic R. A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference. J Infect. 2022;S0163-4453:00672\u20137.","journal-title":"J Infect"},{"key":"2004_CR16","first-page":"00032","volume":"S1198-743X","author":"J Deng","year":"2023","unstructured":"Deng J, Rayner D, Ramaraju HB, Abbas U, Garc\u00eda C, Heybati K, et al. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;S1198-743X:00032\u20130.","journal-title":"Clin Microbiol Infect"},{"key":"2004_CR17","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","volume":"8","author":"D Seftel","year":"2021","unstructured":"Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of Coronavirus Disease 19. Open Forum Infect Dis. 2021;8:ofab050.","journal-title":"Open Forum Infect Dis"},{"key":"2004_CR18","doi-asserted-by":"publisher","unstructured":"Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, dos Santos CVQ, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021:S2214109X21004484. https:\/\/doi.org\/10.1016\/S2214-109X(21)00448-4.","DOI":"10.1016\/S2214-109X(21)00448-4"},{"key":"2004_CR19","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292\u2013300.","journal-title":"JAMA"},{"key":"2004_CR20","doi-asserted-by":"publisher","unstructured":"Calusic M, Marcec R, Luksa L, Jurkovic I, Novac N, Mihaljevic S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.15126.","DOI":"10.1111\/bcp.15126"},{"key":"2004_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","volume":"387","author":"CT Bramante","year":"2022","unstructured":"Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med. 2022;387:599\u2013610.","journal-title":"N Engl J Med"},{"key":"2004_CR22","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","volume":"9","author":"S Schloer","year":"2020","unstructured":"Schloer S, Brunotte L, Goretzko J, Mecate-Zambrano A, Korthals N, Gerke V, et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9:2245\u201355.","journal-title":"Emerg Microbes Infect"},{"key":"2004_CR23","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.xcrm.2020.100142","volume":"1","author":"A Carpinteiro","year":"2020","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142.","journal-title":"Cell Rep Med"},{"key":"2004_CR24","doi-asserted-by":"crossref","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","volume":"11","author":"DA Rosen","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, Beiter R, Eccles J, Woodfolk JA, et al. Modulation of the sigma-1 receptor\u2013IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266.","journal-title":"Sci Transl Med"},{"key":"2004_CR25","doi-asserted-by":"crossref","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"VP Sukhatme","year":"2021","unstructured":"Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharm. 2021;12:652688.","journal-title":"Front Pharm"},{"key":"2004_CR26","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","volume":"27","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022;27:1898\u2013907.","journal-title":"Mol Psychiatry"},{"key":"2004_CR27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41380-021-01309-5","volume":"27","author":"J Kornhuber","year":"2022","unstructured":"Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase\/ceramide system in COVID-19. Mol Psychiatry. 2022;27:307\u201314.","journal-title":"Mol Psychiatry"},{"key":"2004_CR28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/pgmj.49.577.771","volume":"49","author":"SDM Court","year":"1973","unstructured":"Court SDM. The definition of acute respiratory illnesses in children. Postgrad Med J. 1973;49:771\u20136.","journal-title":"Postgrad Med J"},{"key":"2004_CR29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","volume":"40","author":"HR Schmidt","year":"2019","unstructured":"Schmidt HR, Kruse AC. The molecular function of \u03c3 receptors: past, present, and future. Trends Pharmacol Sci. 2019;40:636\u201354.","journal-title":"Trends Pharmacol Sci"},{"key":"2004_CR30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","volume":"727","author":"T Ishima","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167\u201373.","journal-title":"Eur J Pharmacol"},{"key":"2004_CR31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nm.3214","volume":"19","author":"E Gulbins","year":"2013","unstructured":"Gulbins E, Palmada M, Reichel M, L\u00fcth A, B\u00f6hmer C, Amato D, et al. Acid sphingomyelinase\u2013ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19:934\u20138.","journal-title":"Nat Med"},{"key":"2004_CR32","doi-asserted-by":"crossref","first-page":"100701","DOI":"10.1016\/j.jbc.2021.100701","volume":"296","author":"A Carpinteiro","year":"2021","unstructured":"Carpinteiro A, Gripp B, Hoffmann M, P\u00f6hlmann S, Hoertel N, Edwards MJ, et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;296:100701.","journal-title":"J Biol Chem"},{"key":"2004_CR33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cpt.2317","volume":"110","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharm Ther. 2021;110:1498\u2013511.","journal-title":"Clin Pharm Ther"},{"key":"2004_CR34","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199\u2013212.","journal-title":"Mol Psychiatry"},{"key":"2004_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-01804-5","volume":"12","author":"N Hoertel","year":"2022","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Abell\u00e1n M, et al. Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study. Transl Psychiatry. 2022;12:90.","journal-title":"Transl Psychiatry"},{"key":"2004_CR36","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/jcm11195882","volume":"11","author":"N Hoertel","year":"2022","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Kornhuber J, Gulbins E, Reiersen AM, Lenze E, et al. Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19. JCM. 2022;11:5882.","journal-title":"JCM"},{"key":"2004_CR37","doi-asserted-by":"crossref","first-page":"e2133090","DOI":"10.1001\/jamanetworkopen.2021.33090","volume":"4","author":"T Oskotsky","year":"2021","unstructured":"Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4:e2133090.","journal-title":"JAMA Netw Open"},{"key":"2004_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02109-3","volume":"12","author":"BA Fritz","year":"2022","unstructured":"Fritz BA, Hoertel N, Lenze EJ, Jalali F, Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12:341.","journal-title":"Transl Psychiatry"},{"key":"2004_CR39","doi-asserted-by":"crossref","first-page":"755600","DOI":"10.3389\/fphar.2021.755600","volume":"12","author":"SM Fred","year":"2022","unstructured":"Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et al. Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in vitro. Front Pharm. 2022;12:755600.","journal-title":"Front Pharm"},{"key":"2004_CR40","doi-asserted-by":"crossref","first-page":"e0124522","DOI":"10.1128\/jvi.01245-22","volume":"96","author":"Y Chen","year":"2022","unstructured":"Chen Y, Wu Y, Chen S, Zhan Q, Wu D, Yang C, et al. Sertraline is an effective SARS-CoV-2 entry inhibitor targeting the spike protein. J Virol. 2022;96:e0124522.","journal-title":"J Virol"},{"key":"2004_CR41","doi-asserted-by":"crossref","first-page":"121023","DOI":"10.1016\/j.ijpharm.2021.121023","volume":"607","author":"SE Khater","year":"2021","unstructured":"Khater SE, El-khouly A, Abdel-Bar HM, Al-mahallawi AM, Ghorab DM. Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection. Int J Pharm. 2021;607:121023.","journal-title":"Int J Pharm"},{"key":"2004_CR42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/pharmaceutics13091400","volume":"13","author":"L Brunotte","year":"2021","unstructured":"Brunotte L, Zheng S, Mecate-Zambrano A, Tang J, Ludwig S, Rescher U, et al. Combination therapy with fluoxetine and the nucleoside analog GS-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro. Pharmaceutics. 2021;13:1400.","journal-title":"Pharmaceutics"},{"key":"2004_CR43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/microorganisms9020339","volume":"9","author":"A Dechaumes","year":"2021","unstructured":"Dechaumes A, Nekoua MP, Belouzard S, Sane F, Engelmann I, Dubuisson J, et al. Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms. 2021;9:339.","journal-title":"Microorganisms"},{"key":"2004_CR44","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/bph.15418","volume":"178","author":"S Schloer","year":"2021","unstructured":"Schloer S, Brunotte L, Mecate-Zambrano A, Zheng S, Tang J, Ludwig S, et al. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br J Pharm. 2021;178:2339\u201350.","journal-title":"Br J Pharm"},{"key":"2004_CR45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85049-0","volume":"11","author":"M Zimniak","year":"2021","unstructured":"Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H, et al. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11:5890.","journal-title":"Sci Rep"},{"key":"2004_CR46","doi-asserted-by":"crossref","first-page":"13623","DOI":"10.3390\/ijms232113623","volume":"23","author":"D P\u00e9ricat","year":"2022","unstructured":"P\u00e9ricat D, Leon-Icaza SA, S\u00e1nchez-Rico M, M\u00fchle C, Zoicas I, Schumacher F, et al. Antiviral and anti-inflammatory activities of fluoxetine in a SARS-CoV-2 infection mouse model. Int J Mol Sci. 2022;23:13623.","journal-title":"Int J Mol Sci"},{"key":"2004_CR47","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Ogawa Y, Leucht S, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366.","journal-title":"Lancet."},{"key":"2004_CR48","doi-asserted-by":"crossref","first-page":"e000646","DOI":"10.1136\/bmjresp-2020-000646","volume":"7","author":"B Kirenga","year":"2020","unstructured":"Kirenga B, Muttamba W, Kayongo A, Nsereko C, Siddharthan T, Luisba J, et al. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Resp Res. 2020;7:e000646.","journal-title":"BMJ Open Resp Res"},{"key":"2004_CR49","unstructured":"Jazz Pharmaceuticals. Luvox (fluvoxamine maleate)\u2014full prescribing information. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022235lbl.pdf."},{"key":"2004_CR50","doi-asserted-by":"crossref","first-page":"ITC161","DOI":"10.7326\/AITC202111160","volume":"174","author":"TM Uyeki","year":"2021","unstructured":"Uyeki TM. Influenza. Ann Intern Med. 2021;174:ITC161\u201376.","journal-title":"Ann Intern Med"},{"key":"2004_CR51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"key":"2004_CR52","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n M\u00c1, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550\u201360.","journal-title":"Epidemiology"},{"key":"2004_CR53","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1017\/S2045796021000743","volume":"31","author":"N Hoertel","year":"2022","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Gulbins E, Kornhuber J, Vernet R, Beeker N, et al. Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study. Epidemiol Psychiatr Sci. 2022;31:e18.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2004_CR54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40261-021-01001-0","volume":"41","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. Clin Drug Investig. 2021;41:221\u201333.","journal-title":"Clin Drug Investig"},{"key":"2004_CR55","doi-asserted-by":"crossref","first-page":"e0247122","DOI":"10.1371\/journal.pone.0247122","volume":"16","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS ONE. 2021;16:e0247122.","journal-title":"PLoS ONE"},{"key":"2004_CR56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2307\/3314608","volume":"9","author":"B Efron","year":"1981","unstructured":"Efron B. Nonparametric standard errors and confidence intervals. Can J Stat. 1981;9:139\u201358.","journal-title":"Can J Stat"},{"key":"2004_CR57","unstructured":"Kassambara A, Kosinski M, Biecek P. Survminer: Drawing Survival Curves Using \u201cGgplot2\u201d. 2020. https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"2004_CR58","doi-asserted-by":"publisher","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42. https:\/\/doi.org\/10.18637\/jss.v042.i08.","DOI":"10.18637\/jss.v042.i08"},{"key":"2004_CR59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/2229-3485.173773","volume":"7","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Pramesh C, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7:51.","journal-title":"Perspect Clin Res"},{"key":"2004_CR60","unstructured":"Yang Z. Nnt: the number needed to treat (NNT) for survival endpoint. 2020. https:\/\/CRAN.R-project.org\/package=nnt."},{"key":"2004_CR61","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer; New York, USA; 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"2004_CR62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika."},{"key":"2004_CR63","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Auckland, New Zealand; 2022. https:\/\/www.R-project.org\/."},{"key":"2004_CR64","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1192\/bjo.2021.1053","volume":"8","author":"CL Clelland","year":"2021","unstructured":"Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8:e6.","journal-title":"BJPsych Open"},{"key":"2004_CR65","doi-asserted-by":"crossref","first-page":"111437","DOI":"10.1016\/j.biopha.2021.111437","volume":"138","author":"JF Creeden","year":"2021","unstructured":"Creeden JF, Imami AS, Eby HM, Gillman C, Becker KN, Reigle J, et al. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomed Pharmacother. 2021;138:111437.","journal-title":"Biomed Pharmacother"},{"key":"2004_CR66","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2214-109X(21)00588-X","volume":"10","author":"G Reis","year":"2022","unstructured":"Reis G, Mills E. Fluvoxamine for the treatment of COVID-19\u2014author\u2019s reply. Lancet Glob Health. 2022;10:e333.","journal-title":"Lancet Glob Health"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02004-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:05:01Z","timestamp":1713945901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02004-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02004-3","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NH is an inventor on a patent application related to methods of treating COVID-19 (FIASMA antidepressants), filled by Assistance Publique-Hopitaux de Paris in France. The other authors have no conflicts of interest related to this work to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Compassionate use approval of fluvoxamine for the treatment of COVID-19 was obtained from the Ministry of Health of Uganda (clearance reference no. ADM.180\/O1 dated 2nd January 2022). All patients were informed that this medication was under evaluation by health authorities. Patients willing to be treated with this medication gave verbal informed consent. All data used in this study were collected as part of routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}